(CoQ 10 ; ubiquinone) has a unique function in oxidative phosphorylation and the generation of adenosine triphosphate (3) . The myocardial and skeletal muscle cells of patients with heart failure (HF) are in an energy-starved state; hence any increase in the ability to augment energy production or enhance efficient utilization is certain to have positive functional effects.
COENZYME Q 10 AS A THERAPY
Few nutraceuticals (a type or subcategory of drug) have received as much attention as CoQ 10 . Consider the number of published articles (>10,000 on PubMed), the number of search results on google.com (w7 million), the number of supplements available and sold in stores on the Internet (>100), and the number of diseases it prevents or treats as advertised (nearly all!) or as approved by a regulatory agency (none). The market for CoQ 10 is estimated at w$1 billion annually, and the cost to patients is between $50 and $100 per month for the doses used in clinical trials. Now consider that there has been no major disease state in which a clinical trial has shown overwhelming and replicated efficacy using CoQ 10 .
Has any "antioxidant" therapy shown benefit in the form of reduced mortality or serious morbidity for the treatment or prevention of HF? Does this therapy have value for a patient or a health system given the outcomes of the published data?
OBSERVATIONAL DATA ON COENZYME Q 10 
LEVELS IN HEART FAILURE
Although associations linking low levels of blood From the Canadian VIGOUR Centre, University of Alberta, Edmonton, Canada. Dr. Ezekowitz has reported that he has no relationships relevant to the contents of this paper to disclose. WILL COENZYME Q 10 BECOME A
GUIDELINE-DIRECTED MEDICAL THERAPY?
Enthusiastically, the investigators have said that
CoQ 10 "should be added as standard therapy" based on these results, and additionally, it is a "natural and safe substance" (12) . 
